Acute leukemia
Conditions
Interventions
Case series:Low-dose TBI combined with flundarabine, arabinoside and cyclophosphamide (FACT) for allogeneic hematopoietic stem cell transplantation
Sponsors
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Basic standard 1. Aged 14 to 65 years; 2. ECOG score =2 times; 3. Patients with persistent extramedullary leukemia and persistent positive MRD; 4. Relapsed ALL was defined as the reappearance of primary cells in blood or bone marrow (>.5%), or any other extramedullary tissue, in patients who had achieved CR.
Exclusion criteria
Exclusion criteria: 1. New or active infection as determined by fever, unexplained pulmonary infiltrate or sinusitis on radiographic assessment which cannot be controlled. Infections diagnosed within 4 weeks of registration must be determined to be controlled or resolving prior to treatment. 2. Suffering from severe heart, liver, renal insufficiency and other diseases; 3.Severe autoimmune disease or immunodeficiency disease; 4. Severe allergic constitution; 5. Severe mental disorders; 6. Have participated in or are currently participating in other clinical trial investigators within the past 3 months. 7.Active CNS leukemia within two weeks of registration. Patients with a history of CNS leukemia must have adequate treatment as defined by at least two negative spinal fluid assessments separated by at least one week. Patients who have received cranial XRT must still be eligible to receive total body irradiation to 4 Gy. 8. Patients planning pregnancy, pregnancy or lactation; 9. The investigator determined that fertile subjects were not using adequate contraceptive methods; 10. The investigator determined that the patient was not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overall survival at day 100 after transplantation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neutrophil recovery time;Platelet recovery time;Primary implantation failed;Acute graft-versus-host disease;Complete remission after transplantation;Relapse after transplantation;Transplantation related mortality;Overall Survival;Progression free survival; | — |
Countries
China
Contacts
Public ContactQian Shenxian
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Outcome results
None listed